Conference Coverage

Cannabis for pain linked to slight risk for arrhythmia


 

FROM ESC CONGRESS 2022

Cancer, musculoskeletal, and neurologic pain

For this analysis, the researchers identified 1.8 million patients in Denmark who were diagnosed with chronic pain between 2018 and 2021.

Of those, around 5,000 patients had claimed at least one prescription of medicinal cannabis (dronabinol 29%, cannabinoids 46%, or cannabidiol 25%).

The patients had a median age of 60 years, and 63% were women.

The cannabis users had been prescribed this therapy for musculoskeletal (35%), cancer (18%), neurological (14%), or other (33%) pain, Dr. Nouhravesh said.

The researchers and Dr. Olshansky have no relevant financial disclosures.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

‘Stunning variation’ in CV test, procedure costs revealed at top U.S. hospitals
MDedge Cardiology
Do ICDs still ‘work’ in primary prevention given today’s recommended HF meds?
MDedge Cardiology
‘Staggering’ CVD rise projected in U.S., especially in minorities
MDedge Cardiology
Using wearable devices to detect AFib ‘cost effective’
MDedge Cardiology
‘Obesity paradox’ in AFib challenged as mortality climbs with BMI
MDedge Cardiology
AHA statement outlines symptoms of common heart diseases
MDedge Cardiology
Atrial cardiopathy linked to 35% higher dementia risk
MDedge Cardiology
Barcelona beckons for first hybrid ESC Congress
MDedge Cardiology
Low-dose edoxaban curbs stroke risk in elderly with AF, despite frailty
MDedge Cardiology
Early menopause linked with increased risk of heart problems
MDedge Cardiology